论文部分内容阅读
目的评价浙江省实施脑膜炎球菌疫苗(Meningococcal Vaccine,MenV)接种成本-效果(Cost Effectiveness,CE)、成本效益(Cost-Benefit,CB),为有关MenV免疫政策和策略的制定提供依据。方法通过自回归移动平均模型测算期望发病与死亡人数,结合8个县现场调查和特尔斐(Delphi)法专家咨询计算成本与疾病负担,对浙江省1978～2007年MenV接种进行CE和CB分析。结果浙江省1978～2007年MenV预防接种投入8562.35万元,通过实施接种,减少流行性脑脊髓膜炎发病77216例、减少死亡35914例,减少的经济损失为25.98亿元。结论接种MenV的CE和CB显著,要继续做好MenV接种,进一步提高接种质量和人群覆盖率。
Objective To evaluate the cost-effectiveness (CE) and cost-benefit (CB) of Meningococcal Vaccine (MenV) vaccination in Zhejiang Province and provide the basis for the formulation of MenV immune policy and strategy. Methods Calculate the expected incidence and death toll by using autoregressive moving average model. Combined with 8 county field surveys and Delphi expert consultation to calculate the cost and disease burden, CE and CB were analyzed for MenV vaccination in Zhejiang Province from 1978 to 2007 . Results MenV vaccination in Zhejiang Province from 1978 to 2007 invested 85.623 million yuan. Through vaccination, 77,216 cases of epidemic meningococcal disease were reduced and 35,914 cases of death were reduced. The economic loss decreased by 2.598 billion yuan. Conclusion The vaccination of MenV with CE and CB was significant. MenV vaccination should be continued to further improve vaccination quality and population coverage.